← 홈

혈액암 (AML/ALL)

858개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 858개
ADCBiologicInstitut CuriesPhase 3

Dexamethasone acetate (Dexamethasone acetate)

Opsoclonus Myoclonus Syndrome; Neuroblastoma · Leukemia

#Leukemia#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 90%임상시험 63상태 DISCONTINUED
CGTBiologicHoffmann-La RochePhase 1

Interferon-Alfa-2b (Interferon-Alfa-2b)

Solid Cancers · Adult T-cell Leukemia-Lymphoma

#AdultT-cellLeukemia-Lymphoma#CGT#Phase1#인기#세포유전치료+5
효능 ORR 24%임상시험 63상태 ACTIVE
AntibodyMerckvedotin after avelumabPhase 1

pembrolizumab (Keytruda, Pembrolizumab (+) Berahyaluronidase alfa)

Advanced or Metastatic Solid Tumors · Metastatic Non-small Cell Lung Cancer

#MetastaticNon-smallCellLungCance#Antibody#Phase1#인기#항체+5
효능 ORR 65.1%임상시험 63상태 ACTIVE
ADCBiologicAstraZenecaPhase 2

Selumetinib (Selumetinib)

Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 19.7%임상시험 63상태 RECRUITING
CGTBiologicNeotropixPhase 1

biological agent (Seneca Valley Virus, Seneca Valley Virus (biological agent))

Carcinoid; Neuroendocrine · Carcinoid

#Carcinoid#CGT#Phase1#인기#세포유전치료+5
임상시험 63상태 ACTIVE
CGTBiologicPorteus, Matthew, MDPhase 1

Allogeneic Stem Cell Transplant (Allogeneic Stem Cell Transplant)

Hematologic Diseases · Hematologic Diseases

#HematologicDiseases#CGT#Phase1#인기#세포유전치료+4
효능 ORR 72.7%임상시험 62상태 RECRUITING
CGTBiologicShenzhen BinDeBio Ltd.mayPhase 2

CAR-T cell immunotherapy (CAR-T cell immunotherapy)

B-cell Acute Lymphoblastic Leukemia; Lymphoma · GD2

#GD2#CGT#Phase2#인기#세포유전치료+5
효능 ORR 80.3%임상시험 62상태 ACTIVE
ADCBiologicMedical Enterprises Europe B.V.Phase 3

Mitomycin C (Mitomycin C)

Locally Advanced Cancer in the Anal Region · Urothelial Cancer

#UrothelialCancer#ADC#Phase3#인기#항체약물접합체+4
임상시험 62상태 RECRUITING
ADCBiologicNovartis PharmaceuticalsPhase 2

Mitoxantrone Hydrochloride (Mitoxantrone Hydrochloride)

Leukemia; Myelodysplastic Syndromes · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 30%임상시험 62상태 ACTIVE
CGTBiologicMerck Sharp & Dohme LLCPhase 2

Stem cell infusion (Stem cell infusion)

Leukemia; Lymphoma · Leukemia

#Leukemia#CGT#Phase2#인기#세포유전치료+5
효능 ORR 90%임상시험 62상태 ACTIVE
CGTBiologicYake Biotechnology Ltd.Phase 1

chimeric antigen receptor T cell treatment (chimeric antigen receptor T cell treatment)

T Cell Lymphoma; T-cell Leukemia · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 80.3%임상시험 62상태 ACTIVE
CGTBiologicGenzyme, a Sanofi CompanyPhase 2

stem cells (stem cells)

Acute Lymphoblastic Leukemia; Acute Myelocytic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase2#인기#세포유전치료+5
임상시험 62상태 DISCONTINUED
CGTBiologicAlliance for Clinical Trials in…Phase 3

Allopurinol (Allopurinol)

B Acute Lymphoblastic Leukemia · Fallopian Tube Cancer

#FallopianTubeCancer#CGT#Phase3#인기#세포유전치료+5
임상시험 61상태 DISCONTINUED
CGTBiologicHebei Senlang Biotechnology Inc…Phase 2

Autologous CAR-T cells (Autologous CAR-T cells)

Leukemia; Lymphoma · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
효능 ORR 80.3%임상시험 61상태 ACTIVE
ADCBiologicOHSU Knight Cancer InstitutePhase 1

Bicalutamide (Bicalutamide)

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8 · FRα

#FR#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 19%임상시험 61상태 DISCONTINUED
ADCBiologicJohnson & Johnson Pharmaceutica…Phase 2

Epoetin Alfa (Epoetin Alfa)

Anemia; Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase2#인기#항체약물접합체+5
임상시험 61상태 RECRUITING
ADCBiologicJiangsu HengRui Medicine Co., L…Phase 2

Hydroxydaunomycin (Hydroxydaunomycin)

Richter Syndrome; Chronic Lymphocytic Leukemia · Richter Syndrome

#RichterSyndrome#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 95%임상시험 61상태 RECRUITING
CGTBiologicGlaxoSmithKlineSN-38 also augmented IL-10 …Phase 2

topotecan hydrochloride (topotecan hydrochloride)

Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Cancer

#FallopianTubeCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 95.4%임상시험 61상태 DISCONTINUED
AntibodyRochegovitecan in patients with …Preclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#인기#항체+4
효능 ORR 46.4%임상시험 60상태 ACTIVE
AntibodyJanssenApproved

Teclistamab (Teclistamab)

Myeloma Multiple; Plasma Cell Leukemia · Myeloma Multiple

#MyelomaMultiple#Antibody#Approved#인기#항체+5
임상시험 60상태 RECRUITING

4 / 43 페이지

← 이전다음 →